Jorge M. Gomez - 03 Dec 2021 Form 4 Insider Report for Pear Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 03 Dec 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Dec 2021, 16:26:57 UTC
Prior SEC filing: 09 Nov 2021
Next SEC filing: 19 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Stacie S. Aarestad, Attorney-in-Fact

Key filing fact

Jorge M. Gomez filed Form 4 for Pear Therapeutics, Inc. on 07 Dec 2021.

Key facts

This page summarizes Jorge M. Gomez's Form 4 filing for Pear Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Dec 2021, 16:26.

Change

Previous filing in this sequence was filed on 09 Nov 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PEARQ transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +70,675
Change %
Price
Shares after: 70,675
Date: 03 Dec 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 70,675
Exercise price: $9.28
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

33% of the shares underlying the option shall vest on August 19, 2022, 33% of the shares underlying the option shall vest on August 19, 2023 and 34% of the shares underlying the option shall vest on August 19, 2024.

Footnote F2

Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of June 21, 2021, by and among Thimble Point Acquisition Corp., Oz Merger Sub, Inc. and Pear Therapeutics (US), Inc. (f/k/a Pear Therapeutics, Inc.) ("Private Pear"), in exchange for an option to acquire 48,000 shares of common stock of Private Pear for $13.65 per share.